150
161.
Hilbert P., Zur Nieden K., Stuttmann R. D-dimer screeninig in surgical
long-term intensive care patients // Anaesthesist., 2005, v.54., p. 210-214.
162.
Hillyard C.J., Blake A.S., Wilson K. et al. A latex agglutination assay for
D dimer: evaluation and application to the diagnosis of thrombotic disease // Clin.
Chem., 1987, v.33, p. 1837-1840.
163.
Hoesel L.M., Ward P.A. Mechanisms of inflammatory response
syndrome in sepsis // Drag Discovery Today: Dis. Mex., 2004, v.1, p. 345-350.
164.
Hofman M., Rest A., Hafner G. et al. D-dimer, thrombin- antitrombin
III- complex (TAT) and prothrombin fragment 1+2 (PTF). Parameters for
monitoring therapy with low molecular-weigt heparin in coagulation disorders //
Anaesthesist., 1997, v.46, p. 689-696.
165.
Hofmann J.N., Muhlbayer D., Jochum M., Inthorn D. effect of longterm
and high-dose antithrombin supplementation on coagulation and fibrinolysis in
patients with sepsis // Crit. Care Med., 2004,v.32, p. 1851-1859.
166.
Horan J.T., Francis C.W. Fibrin degradation products, fibrin monomer
and soluble fibrin in disseminated intravascular coagulation // Semin. Thromb.
Hemost., 2001, v.27, p. 657-666.
167.
Iba T., Kidokoro A., Yagi Y. The role of endothelium in changes in
procoagulant activity in sepsis // J. Amer. Col. Sur., 1998, v.187, p. 321-329.
168.
Itoh K., Nakao A., Kishimoto W., Takagi H. Heparin effects on
superoxide production by neutrophils // Eur. Surg. Res., 1995, v.27, p. 184-188.
169.
Iuliano L., Pedersen J.Z., Pratico D. et al. Role of hydroxyl radicals in
the activation of human platelets // Eur. J. Biochem., 1994, v. 221, p. 695-704.
170.
Iuliano L., Colavita A.R., Leo R. et al. Oxygen free radicals and platelet
activation // Free Radic. Biol. Med., 1997, v.22, p. 999-1006.
171.
Janero D.R., Yarwood C. Oxidative modulation and inactivation of
rabbit cardiac adenylate deaminase // Biochem. J., 1995, v.306, p. 421-427.
172.
Jansen M.J., Hendriks T., Hermsen R. et al. A monoclonal antibody
against tumour necrosis factor-alpha improves survival in experimental multiple
organ dysfunction syndrome // Cytokine, 1998, v.10, p. 904-910.
151
173.
Jang I.K., Hursting H.J. When heparins promote thrombosis. Review of
heparin-induced thrombocytopenia // Circulation, 2005, v.111, p. 2671-2683.
174.
Kakkar A.K. Low- and ultra-low-molecular-weight heparins // Best Prac.
Res. Clin. Haematol., 2004, v.17, p. 77-87.
175.
Kang J., Kambayashi J., sakon M. et al. Postoperative changes in
hemostasis analyzed by the serial determination of fibrinopeptides and D-dimer //
Jpn. J. Surg., 1989, v.19, p. 262-268.
176.
Kaplan K.L. Coagulation activation in sepsis // Crit. Care Med.. 2000, v.
28, p. 585-586.
177.
Karima R.K., Matsumoto S., Higashi H., Matsushima K. The molecular
pathogenesis of endotoxic shock and organ failure // Molek. Med. Today., 1999, v.5,
p. 123-132.
178.
Kidokoro A., Iba T., Fukunaga M., Yagi Y. Alterations in coagulation
and fibrinolysis during sepsis // Shock.,1996, v.5, p. 223-228.
179.
Kidokoro A., Iba T., Hong J. Role of DIC in multiple organ failure // Int.
J. Surg. Investig., 2000, v.2, p. 73-80.
180.
Kienast J., Juers M., Wiedemann C.J. et al. Treatment effect of highdose
antithrombin without concomitant heparin in patients with severe sepsis with or
without disseminated intravascular coagulation // J. Thromb. Haemost., 2006, v.4, p.
90-97.
181.
Kinasewitz G.T., Zein J.G., Lee G.L. et al. Prognostic value of a simple
evolving disseminated intravascular coagulation score in patients with severe sepsis //
Crit. Care Med., 2005, v.33, p. 2214-2221.
182.
Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. APACHE II: a
severity of disease classification system // Crit. Care Med., 1985, v.13, p. 818-829.
183.
Knaus W.A., Wagner D.P., Draper E.A. et al. The APACHE III
prognostic system. Risk prediction of hospital mortality for critically ill adults
//Chest., 1991, v.100, p. 1619-1636.
152
184.
Koga S. A novel molecular market for thrombus formation and life
prognosis clinical usefulness of measurement of soluble fibrin monomer-fibrinogen
complex // Rinsho. Byori., 2004, v.52, p. 355-361.
185.
Kountchev J., Bijuklic K., Bellmann R. et al. Reduction D-dimer levels
after therapeutic administration of antithrombin in acquired antithrombin deficiency
of severe sepsis // Critical Care., 2005, v.9, p. 596-600.
186.
Kowalski E., Kopec M., Neiwiarowski S. An evaluation of the
euglobulin method for the determination of fibrinolysis // J. Clin. Pathol., 1959, v.12,
p. 215-218.
187.
Kramer J., Otten H.M., Levi M., ten Cate H. The association of
disseminated intravascular coagulation with specific diseases // Reanimation, 2002,
v.11, p. 575-583.
188.
Larvin M., Mc Mahon M.J. APACHE- II Score for assessment and
monitoring of acute pancreatitis // Lancet, 1989, №2, p.201-205.
189.
Leese T., Shaw D., Holliday M. Prognostic markers in acute pancreatitis:
can pancreatic necrosis be predicted? //Annals Royal College Surgeons of England,
1988, p.227-232.9
190.
Lee L. V., Ewald G. A., Mackenzie C. R., Eisenberg P. R. The
relationship of soluble fibrin and cross-linked fibrin degradation products to the
clinical course of myocardial infarction // Arterioscler. Thrombos. and Vasc. Biol.,
1997, v.17, p. 628-633.
191.
Lee W. L., Downey G.P. Coagulation inhibitors in sepsis and
disseminated intravascular coagulation// Int. Care Med., 2000, v.26, p. 1701-1706.
192.
Lee Y., Shacter E. Role of carbohydrates in oxidative modification
fibrinogen and other plasma proteins // Arch. Biochem. Biophys., 1995, v.321, p.
175-181.
193.
Lentine K.L., Flavin K.E., Gould M.K. Variability in the use of
thromboprophylaxis and outcomes in critically ill medical patients // Am. J.
Medicine, 2005, v.118, p. 1373-1380.
Dostları ilə paylaş: |